Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 90.08 1.80% 1.59
ONCE closed up 1.8 percent on Friday, June 22, 2018, on 2.17 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ONCE trend table...

Date Alert Name Type % Chg
Jun 22 180 Bullish Setup Bullish Swing Setup 0.00%
Jun 22 Calm After Storm Range Contraction 0.00%
Jun 22 Upper Bollinger Band Walk Strength 0.00%
Jun 22 Multiple of Ten Bullish Other 0.00%
Jun 22 Above Upper BB Strength 0.00%
Jun 22 Upper Bollinger Band Touch Strength 0.00%
Jun 21 Jack-in-the-Box Bullish Bullish Swing Setup 1.80%
Jun 21 Upper Bollinger Band Walk Strength 1.80%
Jun 21 Multiple of Ten Bearish Other 1.80%
Jun 21 Inside Day Range Contraction 1.80%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 94.0
52 Week Low 41.06
Average Volume 578,445
200-Day Moving Average 70.1205
50-Day Moving Average 77.9802
20-Day Moving Average 80.3285
10-Day Moving Average 81.159
Average True Range 3.7793
ADX 19.09
+DI 32.56
-DI 13.27
Chandelier Exit (Long, 3 ATRs ) 82.6621
Chandelier Exit (Short, 3 ATRs ) 85.5479
Upper Bollinger Band 89.0407
Lower Bollinger Band 71.6163
Percent B (%b) 1.06
BandWidth 21.69143
MACD Line 2.7023
MACD Signal Line 1.4715
MACD Histogram 1.2308
Fundamentals Value
Market Cap 2.82 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -14.10
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 94.04
Resistance 3 (R3) 93.64 91.92 93.38
Resistance 2 (R2) 91.92 90.91 92.12 93.16
Resistance 1 (R1) 91.00 90.29 91.46 91.40 92.94
Pivot Point 89.28 89.28 89.51 89.48 89.28
Support 1 (S1) 88.36 88.27 88.82 88.76 87.22
Support 2 (S2) 86.64 87.65 86.84 87.00
Support 3 (S3) 85.72 86.64 86.78
Support 4 (S4) 86.12